This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Cancer				
Acute myelogenous leukemia (AML)	Hemopoietic cell kinase (HCK)	SAR and mouse studies suggest HCK inhibitors could be useful for treating AML. SAR studies identified an HCK inhibitor with higher specificity for HCK than for related kinases. In primary cultured AML cells, the compound inhibited tumor growth with nanomolar IC ₅₀ values. In a mouse xenograft model for human AML, the compound prevented tumor growth in bone and spleen. Next steps include preclinical toxicology, pharmacokinetic and pharmacodynamic studies.	Patent pending; available for licensing	Saito, Y. <i>et al. Sci. Transl. Med.</i> ; published online April 17, 2013; doi:10.1126/scitranslmed.3004387 Contact: Fumihiko Ishikawa, RIKEN Research Center for Allergy and Immunology, Yokohama, Japan e-mail: f_ishika@rcai.riken.jp
SciBX 6(19); doi:10.1038/scibx.2013.458 Published online May 16, 2013				